BRCC3 anticorps (N-Term)

N° du produit ABIN318911

L’anticorps anti-BRCC3 Polyclonal Lapin est utilisé pour la détection de BRCC3 dans des échantillons de Humain, Souris et Rat. Il a été validé pour WB et IHC (p).

Aperçu rapide pour BRCC3 anticorps (N-Term) (ABIN318911)

Antigène: BRCC3 (BRCA1/BRCA2-Containing Complex, Subunit 3 (BRCC3))

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp BRCC3 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Détail du produit anti-BRCC3 anticorps

Épitope: N-Term

Specificité: This antibody recognises human BRCA1/BRCA2 complex subunit 36 (BRCC36), a 36.7 kDa nuclear protein.

Purification: Purified

Immunogène: An 18 amino acid peptide from near the amino terminus of human BRCC36.

Isotype: IgG

Information d'application

Indications d'application: Western Blot: 0.5 - 1.0g/mL, detects a band of approximately 36 kDa in MCF7 cell lysates.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Stockage

Concentration: 1.0 mg/mL

Buffer: Phosphate buffered saline containing 0.02 % Sodium Azide (NaN3)

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: 4 °C/-20 °C

Stockage commentaire: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Détails sur BRCC3

Antigène: BRCC3 (BRCA1/BRCA2-Containing Complex, Subunit 3 (BRCC3))

Autre désignation: BRCC3

Sujet: BRCC36, together with BRCA1, BRCA2, Rad51 and BRCC45, forms a holoenzyme complex that possesses an ubiquitin E3 ligase activity. Studies have demonstrated that BRCC36 functions in enhancing cellular survival following DNA damage and that it is essential for ionizing radiation induced BRCA1 phosphorylation and nuclear foci formation. Research has shown that BRCC36 is aberrantly expressed in the majority of breast tumours indicating a potential role in the pathogenesis of the disease. It has been hypothesized that BRCC36 could be a potentially important target in the treatment of radiation-resistant breast tumours.Synonyms: BRCA1-A complex subunit BRCC36, BRCA1/BRCA2-containing complex subunit 3, BRCA1/BRCA2-containing complex subunit 36, BRCC36, BRISC complex subunit BRCC36, C6.1A, CXorf53, Lys-63-specific deubiquitinase BRCC36

ID gène: 79184

NCBI Accession: NP_001018065

UniProt: P46736

Pathways: Positive Regulation of Response to DNA Damage Stimulus